Literature DB >> 6373382

Pregnancy in hyperprolactinemic women.

V Ruiz-Velasco, G Tolis.   

Abstract

Pregnancy achieved in women who receive treatment to correct the secretory dysfunction of nontumoral HPRL or microprolactinomas requires close prenatal care, but generally its course does not vary from normal. When a macroprolactinoma is present, consequences of pregnancy are insignificant, provided the tumor has been previously treated or bromocriptine is given continuously during the pregnancy. On those rare occasions when symptoms of tumor growth appear during pregnancy, bromocriptine and dexamethasone effectively control such manifestations. Breast-feeding of the infant can be allowed, and a second pregnancy within a short term is not contraindicated. When a new pregnancy is not desired, nonhormonal contraceptive methods are advised. Patients with nontumoral HPRL and microadenomas require periodic checkups. Macroadenomas may be surgically excised, but longterm bromocriptine treatment also achieves good results and is highly recommended.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6373382     DOI: 10.1016/s0015-0282(16)47888-x

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  5 in total

Review 1.  Medical management of prolactin-secreting pituitary adenomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

2.  Hyperprolactinemia in Women of Reproductive Age: Etiology, diagnosis, and management.

Authors:  B H Yuen
Journal:  Can Fam Physician       Date:  1992-02       Impact factor: 3.275

Review 3.  Prolactinoma through the female life cycle.

Authors:  Deirdre Cocks Eschler; Pedram Javanmard; Katherine Cox; Eliza B Geer
Journal:  Endocrine       Date:  2017-11-24       Impact factor: 3.633

Review 4.  PRL-secreting pituitary adenomas in pregnancy.

Authors:  I Chiodini; A Liuzzi
Journal:  J Endocrinol Invest       Date:  2003-01       Impact factor: 4.256

5.  Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy.

Authors:  M M Garcia; L P Kapcala
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.